Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT01298011|
Recruitment Status : Completed
First Posted : February 17, 2011
Last Update Posted : June 17, 2015
|Condition or disease||Intervention/treatment||Phase|
|Resectable Pancreatic Cancer||Drug: Gemcitabine and Abraxane||Phase 2|
The best outcome for a patient diagnosed with pancreatic cancer is surgery. However many patients have recurrence of the cancer after successful surgery. The investigators are evaluating chemotherapy before surgery, which is a new approach.
In this study, Abraxane and gemcitabine will be tested as treatment for people with operable pancreatic cancer to see if surgery can be successfully performed and if treatment will reduce cancer cells in the tumor at surgery.
Abraxane is approved by the US FDA for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Gemcitabine is approved by the FDA for first line treatment for patients with locally advanced or metastatic cancer of the pancreas.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||May 2015|
|Experimental: Gemcitabine & Abraxane Pancreatic Cancer||
Drug: Gemcitabine and Abraxane
3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
- Grade III/IV histological response in tumor specimen rate after induction therapy. [ Time Frame: At time of surgery ]
- Number of participants with adverse events. [ Time Frame: From the initial dose of study drug up to 28 days after last dose of study drug. ]
- Tumor response rate to therapy. [ Time Frame: Baseline and 16 weeks ]Pre and post therapy radiological assessments of the primary tumor will be compared using RECIST criteria.
- Change in CA 19-9 [ Time Frame: Baseline, Day 1 of each cycle, and end of therapy. ]Baseline CA19-9 and subsequent levels will be compared.
- Resection rate at surgery [ Time Frame: At time of surgery ]The number of patients who have R0 and R1 surgery will be compiled.
- Time to recurrence [ Time Frame: Time from first dose of study drug to date of first documented progression or date of death, whichever occurs first, assessed up to 60 months. ]
- SPARC protein expression in tumor [ Time Frame: At time of surgery ]
- Overall Survival [ Time Frame: Time from the first dose of study drug until date of death from any cause, up to 60 months. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298011
|United States, Arizona|
|TGen Clinical Research Services at Scottsdale Healthcare|
|Scottsdale, Arizona, United States, 85258|
|United States, Michigan|
|St Mary's / Trinity Health Care|
|Grand Rapids, Michigan, United States, 49505|
|United States, Minnesota|
|Virginia Piper Cancer Institute|
|Minneapolis, Minnesota, United States, 55408|
|United States, Pennsylvania|
|University of Pittsburg Medical Center|
|Pittsburg, Pennsylvania, United States, 19047|
|Principal Investigator:||Ramesh K. Ramanathan, MD||TGen Drug Development|